This company has been acquired
Forma Therapeutics Holdings Management
Management criteria checks 1/4
Key information
Frank Lee
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 6.66% |
| CEO tenure | 3.6yrs |
| CEO ownership | n/a |
| Management average tenure | 1.5yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$190m |
| Mar 31 2022 | n/a | n/a | -US$181m |
| Dec 31 2021 | US$9m | US$620k | -US$173m |
| Sep 30 2021 | n/a | n/a | -US$151m |
| Jun 30 2021 | n/a | n/a | -US$136m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$6m | US$575k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$74m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$442k | -US$53m |
Compensation vs Market: Frank's total compensation ($USD9.31M) is above average for companies of similar size in the US market ($USD4.11M).
Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.
CEO
Frank Lee (54 yo)
3.6yrs
Tenure
US$9,307,807
Compensation
Mr. Frank D. Lee is Chair of the Board of Catamaran Bio, Inc. from April 2022. He serves as an Independent Director at Bolt Biotherapeutics, Inc. since November 2021. Mr. Lee is Chief Executive Officer of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$9.31m | no data | |
| Senior VP & CFO | 3.1yrs | US$3.03m | 0% $ 0 | |
| Senior VP & Chief Technology Officer | 1.3yrs | no data | 0% $ 0 | |
| Senior VP & Chief Scientific Officer | 2.5yrs | no data | 0.087% $ 829.8k | |
| Head of Investor Relations | no data | no data | no data | |
| Senior VP | 3.1yrs | no data | 0% $ 0 | |
| Vice President of Commercial Strategy & Marketing | less than a year | no data | no data | |
| Senior Vice President & Chief Human Resources Officer | less than a year | no data | no data | |
| Senior Vice President of Commercial | 1.8yrs | no data | 0% $ 0 | |
| Senior VP & Chief Patient Officer | less than a year | no data | no data | |
| Executive Vice President | less than a year | no data | no data | |
| Treasurer | no data | no data | no data |
1.5yrs
Average Tenure
57yo
Average Age
Experienced Management: FMTX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.8yrs | US$9.31m | no data | |
| Independent Non-Executive Director | 2.1yrs | US$253.39k | 0% $ 0 | |
| Independent Non-Executive Chairman | 9.9yrs | US$294.14k | 0% $ 0 | |
| Independent Non-Executive Director | 8yrs | US$265.14k | 0% $ 0 | |
| Independent Non-Executive Director | 4.6yrs | US$253.64k | 0% $ 0 | |
| Independent Non-Executive Director | 2.8yrs | US$253.39k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 2.3yrs | US$255.02k | 0% $ 0 |
3.3yrs
Average Tenure
60yo
Average Age
Experienced Board: FMTX's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/16 23:19 |
| End of Day Share Price | 2022/10/13 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Forma Therapeutics Holdings, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Tiago Fauth | Credit Suisse |